Select Issuer Clients

Select Issuer Clients

Issuer Client Profile

PROLOR Biotech, Inc. (acquired by OPKO Health, Inc.)

PROLOR Biotech, Inc. (PBTH) is developing proprietary versions of already- approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. Prolor Biotech was sold for over $500 Million to OPKO Health (OPK) in August 2013.

View Website

Issuer Client News Feed

For Investors

Want to take part in the next big idea?

Join Our Network

For Entrepreneurs

Want to explore how we add value?

Submit Your Business Plan